Isentress is now indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients >4 weeks of age, weighing ≥3kg–<20kg.
Isentress inhibits the catalytic activity of HIV-1 integrase, an HIV-1 encoded enzyme that is required for viral replication. Inhibition of integrase prevents the covalent insertion, or integration, of unintegrated linear HIV-1 DNA into the host cell genome preventing the formation of the HIV-1 provirus.
Isentress is now available as an oral suspension, chewable tablets, and film-coated tablets. Isentress for oral suspension is expected to be available during the 3rd quarter of 2014.
For more information call (800) 850-3430 or visit Isentress.com.